1. Petrick JL, Florio AA, Znaor A, et al. (2020) International trends in hepatocellular carcinoma incidence, 1978-2012. Int J Cancer, 147(2): 317-330. [
DOI:10.1002/ijc.32723]
2. Zhang CH, Cheng Y, Zhang S, et al. (2022) Changing epidemiology of hepatocellular carcinoma in Asia. Liver Int, 42(9): 2029-2041. [
DOI:10.1111/liv.15251]
3. Hartke J, Johnson M, Ghabril M (2017) The diagnosis and treatment of hepatocellular carcinoma. Semin Diagn Pathol, 34(2): 153-159. [
DOI:10.1053/j.semdp.2016.12.011]
4. Llovet JM, Kelley RK, Villanueva A, et al. (2021) Hepatocellular carcinoma. Nat Rev Dis Primers, 7(1): 6. [
DOI:10.1038/s41572-020-00240-3]
5. Li G, Hu L, Wang Y, Wang X, Zeng Q, Xu Z, et al. (2021) Prediction of histologic differentiation grade of hepatocellular carcinoma by magnetic resonance imaging with hepatospecific contrast agent. Int J Radiat Res, 19 (4): 791-799 [
DOI:10.52547/ijrr.19.4.4]
6. Anwanwan D, Singh SK, Singh S, et al. (2020) Challenges in liver cancer and possible treatment approaches. Biochim Biophys Acta Rev Cancer, 1873(1): 188314. [
DOI:10.1016/j.bbcan.2019.188314]
7. Chen W, Chiang CL, Dawson LA (2021) Efficacy and safety of radiotherapy for primary liver cancer. Chin Clin Oncol, 10(1): 9. [
DOI:10.21037/cco-20-89]
8. Kalogeridi MA, Zygogianni A, Kyrgias G, et al. (2015) Role of radiotherapy in the management of hepatocellular carcinoma: A systematic review. World J Hepatol, 7(1): 101-12. [
DOI:10.4254/wjh.v7.i1.101]
9. Saw CB and Li S (2018) 3D treatment planning systems. Med Dosim, 43(2): 103-105. [
DOI:10.1016/j.meddos.2018.03.002]
10. Racka I, Majewska K, Winiecki J (2023) Three-dimensional conformal radiotherapy (3D-CRT) vs. volumetric modulated arc therapy (VMAT) in deep inspiration breath-hold (DIBH) technique in left-sided breast cancer patients-comparative analysis of dose distribution and estimation of projected secondary cancer risk. Strahlenther Onkol, 199(1): 90-101. [
DOI:10.1007/s00066-022-01979-2]
11. Asagi A, Sakaguchi C, Nadano S, et al. (2022) Efficacy and safety of three-dimensional conformal radiotherapy for macroscopic vascular invasion of hepatocellular carcinoma. Acta Med Okayama, 76(6): 679-688.
12. Lim DH, Lee H, Park HC, et al. (2013) The efficacy of high-dose 3-dimensional conformal radiation therapy in patients with small hepatocellular carcinoma not eligible for other local modalities. Am J Clin Oncol, 36(2): 162-6. [
DOI:10.1097/COC.0b013e3182438dae]
13. Luh JY, Albuquerque KV, Cheng C, et al. (2020) ACR-ASTRO practice parameter for image-guided radiation therapy (IGRT). Am J Clin Oncol, 43(7): 459-468. [
DOI:10.1097/COC.0000000000000697]
14. Grégoire V, Guckenberger M, Haustermans K, et al. (2020) Image guidance in radiation therapy for better cure of cancer. Mol Oncol, 14(7): 1470-1491. [
DOI:10.1002/1878-0261.12751]
15. Takeda A, Sanuki N, Tsurugai Y, et al. (2016) Phase 2 study of stereotactic body radiotherapy and optional transarterial chemoembolization for solitary hepatocellular carcinoma not amenable to resection and radiofrequency ablation. Cancer, 122(13): 2041-9. [
DOI:10.1002/cncr.30008]
16. Garin E, Tselikas L, Guiu B, et al. (2021) Personalized versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomized, multicenter, open-label phase 2 trial. Lancet Gastroenterol Hepatol, 6(1): 17-29. [
DOI:10.1016/S2468-1253(20)30290-9]
17. Zou LQ, Zhang BL, Chang Q, et al. (2014) 3D conformal radiotherapy combined with transcatheter arterial chemoembolization for hepatocellular carcinoma. World J Gastroenterol, 20(45): 17227-34. [
DOI:10.3748/wjg.v20.i45.17227]
18. Dracham CB, Mahajan R, Rai B, et al. (2019) Toxicity and clinical outcomes with definitive three-dimensional conformal radiotherapy (3DCRT) and concurrent cisplatin chemotherapy in locally advanced cervical carcinoma. Jpn J Clin Oncol, 49(2): 146-152. [
DOI:10.1093/jjco/hyy164]
19. Su F, Chen K, Liang Z, et al. (2019) Survival benefit of higher fraction dose delivered by three-dimensional conformal radiotherapy in hepatocellular carcinoma smaller than 10 cm in size. Cancer Manag Res, 11: 3791-3799. [
DOI:10.2147/CMAR.S179540]
20. Zelefsky MJ, Kollmeier M, Cox B, et al. (2012) Improved clinical outcomes with high-dose image guided radiotherapy compared with non-IGRT for the treatment of clinically localized prostate cancer. Int J Radiat Oncol Biol Phys, 84(1): 125-9. [
DOI:10.1016/j.ijrobp.2011.11.047]
21. Becker-Schiebe M, Abaci A, Ahmad T, et al. (2016) Reducing radiation-associated toxicity using online image guidance (IGRT) in prostate cancer patients undergoing dose-escalated radiation therapy. Rep Pract Oncol Radiother, 21(3): 188-94. [
DOI:10.1016/j.rpor.2016.01.005]
22. Zhang H, Chen Y, Hu Y, et al. (2019) Image-guided intensity-modulated radiotherapy improves short-term survival for abdominal lymph node metastases from hepatocellular carcinoma. Ann Palliat Med, 8(5): 717-727. [
DOI:10.21037/apm.2019.11.17]
23. Kurniawan J, Gani RA, Hasan I, et al. (2020) The improvement in 1-year survival rate of patients with hepatocellular carcinoma BCLC stage A and B after the implementation of comprehensive management. J Gastrointest Cancer, 51(3): 829-835. [
DOI:10.1007/s12029-019-00298-7]
24. Liu J, Zhang J, Wang Y, et al. (2022) HAIC versus TACE for patients with unresectable hepatocellular carcinoma: A systematic review and meta-analysis. Medicine (Baltimore), 101(51): e32390. [
DOI:10.1097/MD.0000000000032390]
25. Yoon HI, Lee IJ, Han KH, et al. (2014) Improved oncologic outcomes with image-guided intensity-modulated radiation therapy using helical tomotherapy in locally advanced hepatocellular carcinoma. J Cancer Res Clin Oncol, 140(9): 1595-605. [
DOI:10.1007/s00432-014-1697-0]
26. Chen YJ, Suh S, Nelson RA, et al. (2012) Setup variations in radiotherapy of anal cancer; advantages of target volume reduction using image-guided radiation treatment. Int J Radiat Oncol Biol Phys, 84(1): 289-95. [
DOI:10.1016/j.ijrobp.2011.10.068]
27. Choi SH and Seong J (2018) Strategic application of radiotherapy for hepatocellular carcinoma. Clin Mol Hepatol, 24(2): 114-134. [
DOI:10.3350/cmh.2017.0073]